Arocho-Quinones Elsa V, Lew Sean M, Handler Michael H, Tovar-Spinoza Zulma, Smyth Matthew D, Bollo Robert J, Donahue David, Perry M Scott, Levy Michael, Gonda David, Mangano Francesco T, Kennedy Benjamin C, Storm Phillip B, Price Angela V, Couture Daniel E, Oluigbo Chima, Duhaime Ann-Christine, Barnett Gene H, Muh Carrie R, Sather Michael D, Fallah Aria, Wang Anthony C, Bhatia Sanjiv, Eastwood Daniel, Tarima Sergey, Graber Sarah, Huckins Sean, Hafez Daniel, Rumalla Kavelin, Bailey Laurie, Shandley Sabrina, Roach Ashton, Alexander Erin, Jenkins Wendy, Tsering Deki, Price George, Meola Antonio, Evanoff Wendi, Thompson Eric M, Brandmeir Nicholas
Departments of1Neurosurgery and.
3Department of Neurosurgery, Children's Hospital of Wisconsin, Milwaukee, Wisconsin.
J Neurosurg Pediatr. 2023 Mar 3:1-14. doi: 10.3171/2022.12.PEDS22282.
The authors of this study evaluated the safety and efficacy of stereotactic laser ablation (SLA) for the treatment of drug-resistant epilepsy (DRE) in children.
Seventeen North American centers were enrolled in the study. Data for pediatric patients with DRE who had been treated with SLA between 2008 and 2018 were retrospectively reviewed.
A total of 225 patients, mean age 12.8 ± 5.8 years, were identified. Target-of-interest (TOI) locations included extratemporal (44.4%), temporal neocortical (8.4%), mesiotemporal (23.1%), hypothalamic (14.2%), and callosal (9.8%). Visualase and NeuroBlate SLA systems were used in 199 and 26 cases, respectively. Procedure goals included ablation (149 cases), disconnection (63), or both (13). The mean follow-up was 27 ± 20.4 months. Improvement in targeted seizure type (TST) was seen in 179 (84.0%) patients. Engel classification was reported for 167 (74.2%) patients; excluding the palliative cases, 74 (49.7%), 35 (23.5%), 10 (6.7%), and 30 (20.1%) patients had Engel class I, II, III, and IV outcomes, respectively. For patients with a follow-up ≥ 12 months, 25 (51.0%), 18 (36.7%), 3 (6.1%), and 3 (6.1%) had Engel class I, II, III, and IV outcomes, respectively. Patients with a history of pre-SLA surgery related to the TOI, a pathology of malformation of cortical development, and 2+ trajectories per TOI were more likely to experience no improvement in seizure frequency and/or to have an unfavorable outcome. A greater number of smaller thermal lesions was associated with greater improvement in TST. Thirty (13.3%) patients experienced 51 short-term complications including malpositioned catheter (3 cases), intracranial hemorrhage (2), transient neurological deficit (19), permanent neurological deficit (3), symptomatic perilesional edema (6), hydrocephalus (1), CSF leakage (1), wound infection (2), unplanned ICU stay (5), and unplanned 30-day readmission (9). The relative incidence of complications was higher in the hypothalamic target location. Target volume, number of laser trajectories, number or size of thermal lesions, or use of perioperative steroids did not have a significant effect on short-term complications.
SLA appears to be an effective and well-tolerated treatment option for children with DRE. Large-volume prospective studies are needed to better understand the indications for treatment and demonstrate the long-term efficacy of SLA in this population.
本研究的作者评估了立体定向激光消融术(SLA)治疗儿童药物难治性癫痫(DRE)的安全性和有效性。
17个北美中心参与了该研究。对2008年至2018年间接受SLA治疗的DRE儿科患者的数据进行了回顾性分析。
共确定了225例患者,平均年龄12.8±5.8岁。感兴趣靶点(TOI)位置包括颞叶外(44.4%)、颞叶新皮质(8.4%)、颞叶内侧(23.1%)、下丘脑(14.2%)和胼胝体(9.8%)。分别有199例和26例使用了Visualase和NeuroBlate SLA系统。手术目标包括消融(149例)、离断(63例)或两者兼有(13例)。平均随访时间为27±20.4个月。179例(84.0%)患者的目标发作类型(TST)有所改善。167例(74.2%)患者报告了恩格尔分类;排除姑息性病例后,分别有74例(49.7%)、35例(23.5%)、10例(6.7%)和30例(20.1%)患者的恩格尔分类为I、II、III和IV级。对于随访时间≥12个月的患者,分别有25例(51.0%)、18例(36.7%)、3例(6.1%)和3例(6.1%)患者的恩格尔分类为I、II、III和IV级。有SLA术前与TOI相关手术史、皮质发育畸形病理学以及每个TOI有2条以上轨迹的患者,癫痫发作频率改善的可能性较小和/或预后较差。更多数量的较小热损伤与TST的更大改善相关。30例(13.3%)患者出现了51例短期并发症,包括导管位置不当(3例)、颅内出血(2例)、短暂性神经功能缺损(19例)、永久性神经功能缺损(3例)、症状性病灶周围水肿(6例)、脑积水(1例)、脑脊液漏(1例)、伤口感染(2例)、计划外入住重症监护病房(5例)和计划外30天再入院(9例)。下丘脑靶点位置的并发症相对发生率较高。靶点体积、激光轨迹数量、热损伤数量或大小以及围手术期使用类固醇对短期并发症没有显著影响。
SLA似乎是治疗儿童DRE的一种有效且耐受性良好的治疗选择。需要进行大规模的前瞻性研究,以更好地了解治疗指征并证明SLA在该人群中的长期疗效。